LY2228820,
LY2228820 dimesylate,
LY2228820,
862507-23-1,
Ralimetinib Mesylate,
Ralimetinib dimesylate,
UNII-QUW7B71FO9,
LY2228820 diMesylate,
LY-2228820,
QUW7B71FO9,
Ralimetinib mesylate [USAN],
LY2228820 2MsOH,
LY 2228820,
Ralimetinib mesylate (USAN),
5-(2-(tert-butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate,
5-(2-(tert-butyl)-4-(4-fluorophenyl)-1h-imidazol-5-yl)-3-(2,2-dimethylpropyl)-3h-imidazo(4,5-b)pyridin-2-amine methanesulfonate,
5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate,
LY-2228820 dimesylate,
Ralimetinib (LY2228820),
SCHEMBL3992244,
CHEMBL2364627,
SCHEMBL16347433,
DTXSID60235457,
NARMJPIBAXVUIE-UHFFFAOYSA-N,
BCPP000179,
HMS3654J16,
BCP02295,
EX-A2289,
Ralimetinib 2MsOH(LY2228820),
MFCD17169991,
LY2228820; Ralimetinib dimesylate,
BCP9000872,
CS-0208,
KS-00000T78,
LSN-2322600,
3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, methanesulfonate (1:2),
AK176011,
HY-13241,
FT-0670881,
SW220068-1,
D10659,
W-5947,
J-516068,
LY-2228820, LY2228820,
5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine;methanesulfonic acid,
5-[2-tert-Butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate,
5-[2-tert-butyl-5-(4-fluorophenyl)-3H-imidazol-4-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine dimesylate,
cc-430,
862507-23-1 (mesylate),
CID11570805,
CID 11570805,
A5566,
A10545,
862505-00-8,